To evaluate the efficacy and safety of adding pembrolizumab to neoadjuvant chemotherapy in improving pathologic complete response rates among women with early-stage breast cancer.
Interventional clinical trial registered under ClinicalTrials.gov Identifier: NCT01042379.
Administered pembrolizumab in combination with neoadjuvant chemotherapy regimens to female participants diagnosed with early-stage breast cancer.
Assessed pathologic complete response rates in resected tumor tissue following neoadjuvant therapy.
Neoadjuvant pembrolizumab combined with chemotherapy led to improved rates of pathologic complete response relative to baseline expectations.
Treatment responses supported the clinical utility of immune checkpoint blockade prior to surgical resection in early-stage breast cancer.